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Seven patients with severe chronic congestive heart fail-
ure were treated with a new cardiotonic agent, WIN
47203 (an analog of amrinone), for an average of 7.4
weeks (range 2 to 15). At the initiation of therapy, hemo-
dynamic improvement occurred in all patients as the
cardiac index increased from 1.79 ± 0.39 to 2.30 ±
0.44 liters/min per m2 (probability [p] < 0.05) and pul-
monary capillary wedge pressure decreased from 24.1
± 6.7 to 16.1 ± 7.8 mm Hg (p < 0.05). Long-term
therapy produced a substantial symptomatic improve-
ment in fiveof the seven patients. This improvement was
fully sustained in two patients and the remaining three
experienceda partial return oftheir symptomseventhough
the initial hemodynamic improvements at rest remained
WIN 47203, an analog of amrinone. is a recently synthe-
sized, nonglycosidic, nonadrenergic cardiotonic agent that
also produces peripheral vascular dilation (I), Amrinone
itself has been of considerable interest in the treatment of
severe congestive heart failure because it is an orally active
agent that improves the performance of the failing heart as
characterized by substantial increments in cardiac output
and decrements in ventricular filling pressure without tachy-
cardia or a change in arterial pressure, However, these ben-
efits have been associated with substantial side effects. most
notably gastrointestinal intolerance (2), WIN 47203 has po-
tential advantages relative to amrinone in being a much more
potent inotropic agent, apparently free of the side effects
that have complicated long-term therapy with amrinone (3),
To determine the long-term efficacy of a cardiotonic agent.
it is necessary either to compare the effects of the drug
versus placebo in a double-blind fashion as done by Chia-
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evident in all seven patients. Withdrawal of WIN 47203
precipitated hemodynamic deterioration in all patients.
The cardiac index decreased from 2.25 ± 0.40 to 1.64
± 0.46 liters/min per m2 (p < 0.05) while the pulmonary
capillary wedge pressure increased from 17.1 ± 7.8 to
23.2 ± 12.0 mm Hg (p < 0.05). Stroke volume index
after withdrawal was lower than the control level before
therapy (17.0 ± 6.6 versus 20.3 ± 4.7 ml/nr': p < 0.05)
and pulmonary capillary wedge pressure was similar.
During long-term therapy, no undesirable side effects or
hematologic changes were observed.
Thus, drug-dependent hemodynamic benefits and ap-
parent progression of the underlying cardiac disease were
demonstrated during long-term therapy with WIN 47203.
sen Lee et al. (4) or to study the effects of withdrawal and
reinstitution of therapy on objective variables using the pa-
tient as his or her own control as done by Arnold et al. (5),
Although the former approach is generally preferred when
the hemodynamic. clinical and adverse effects of the drug
have been established, the latter IS more convenient when
the cardiotonic agent is still at an early stage of development.
In the present study. the hemodynamiceffects of WIN 47203
were evaluated during initiation. maintenance, withdrawal
and reinstitution of therapy.
Methods
Patients. Five men and two women with severe chronic
congestive heart failure were offered therapy with WIN
47203. The average patient age was 58.8 years (range 49
to 6 I). The cause of heart failure was coronary artery disease
in five patients and idiopathic cardiomyopathy in the re-
maining two. Despiteoptimal therapy with digitalis. diuretic
drugs and nitrates. all patients were severely restricted in
activity by fatigue and dyspnea and not by angina. Their
physical activity was compatible with functional class III-
IV of the New York Heart Association. Maximal oxygen
uptake averaged 9.4 mllkg per min (range 7 to 11.6), The
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digoxin level averaged 1.1 ± 0 .5 ng/m\. Five patients were
in sinus rhythm and two were in atrial fibrillation. Left
ventricular eject ion fraction determined by the gated radio-
nuclide technique averaged 20% (range 15 to 27).
Patients continued to receive their usual daily doses of
digitalis glycosides and diuretic drugs throughout the study.
Nitrates were discontinued and a strict dietary regimen in-
cluding 2 g of sodium was prescribed. The nature , potential
benefits and possible risks of the study were ful1y explained
to the patients who then gave informed consent. The pro-
tocol was approved by the Committee on Clinical Investi-
gations of the Albert Einstein Col1ege of Medicine.
Hemodynamics. Patient s were admitted to the coronary
care unit for study. After 24 hours of bedrest, they under-
went right heart catheterization performed with a flow-di-
rected bal1oon-tipped thermodilution catheter (Edwards
Laboratories). Mean pulmonary artery , pulmonary wedge
and right atrial pressures were recorded on a photographic
recorder (Electronics for Medicine). Systemic arterial pres-
sure was measured either directly with an indwelling cath-
eter inserted percutaneously into the radial artery or by the
standard cuff technique. In the latter case, mean systemic
arterial pressure was taken as diastolic pressure plus one-
third of the pulse pressure. Cardiac output was measured in
triplicate by the thermodilution technique to less than a 10%
variation . Derived hemodynamic variables including cardiac
index , stroke volume index and systemic vascular resistance
were calculated from standard formulas . An electrocardio-
graphic lead was monitored continuously throughout the
hemodynamic study .
Exercise capacity assessment. Exercise was performed
on a treadmil1 according to the protocol of Patterson et a\.
(6). Patients were tested at the same time of the day, at least
4 hours after taking their medication. Before therapy with
WIN 47203 , two exercise tests were performed to determine
reproducibility. Measurements of mixed expired oxygen,
mixed expired carbon dioxide , expired volume , expired gas
temperature and barometric pressure were performed at rest
and every 30 seconds throughout exercise using a metabolic
measurement cart (Beckman Instruments). Patients were
breathing through a mouthpiece attached to a low resistance
nonrebreathing, three-way valve with a nose clamp . The
oxygen analyzer (OM- I I , Beckman Instruments) and car-
bon dioxide analyzer (LB-2, Beckman Instrument s) were
calibrated using an analyzed mixture of approximately 4%
carbon dioxide and 16% oxygen in nitrogen . This calibration
was made within 1 hour of the testing. Oxygen uptake (mil
kg per min) was calcul ated using standard formulas (7).
Maximal oxygen uptake was defined by the failure of oxygen
uptake to further augment despite a higher work load (8).
Outpatient follow-up. After discharge from the hos-
pital , patients were asked to weigh themselves daily and
maintain a diary of their symptoms. They were evaluated
weekly during the first month of therapy with WIN 47203
and biweekly thereafter. At each visit , blood samples were
withdrawn for clinical laboratory tests and urinaly sis was
performed. A graded exercise stress test with measurement
of maximal oxygen uptake was performed after 1 to 2 weeks
of therapy and before withdrawal of WIN 47203 .
Drug administration and withdrawal. At initiation of
therapy with WIN 47203, the oral dose was titrated to produce
an increa se in cardiac index of at least 30% above normal.
This end point was achieved with a dose of 2.5 mg in two
patients and 5 mg in the other five. Long-term therapy was
then admini stered at 6 hour intervals and hemod ynamic
monitoring was discontinued.
During long-term therapy. all patients were rehospital-
ized for hemodynamic monitoring during withdrawal of WIN
47203. Patients who failed to manifest symptomatic im-
provement were the first to be readmitted after 2 to 3 weeks
of therap y. Some patients, although their condition was
substantial1y improved, experienced a return of some of their
symptoms after 6 to 9 weeks of therapy. They were read-
mitted at that time for withdrawa l of WIN 47203. Patients
who experienced a steady clinical improvement were read-
mitted electively after at least 9 weeks of therapy.
Statistical analysis. Results are expressed as means ±
standard deviation and are considered significantly different
at a probability [p] value less than 0.05. Comparisons of
the hemodynamic responses during initiation and with-
drawal of therapy with WIN 47203 were made using a two
within subjec ts factor analysis of variance. Analysis of the
effects of WIN 4720 3 at each point in time and time effect
both with and without the drug were performed using a
single degree of freedom contrast.
Compari sons of the hemodyn amic response during with-
drawal and reinstitution of WIN 47203 were made using a
within subject analys is of variance . These comparisons were
made at three times : during long-term therapy with WIN
47203 , during withdrawal of therapy and during its rein-
stitution. Subsequent pair-wise comparisons between the
mean values for each hemodynamic index at the three points
in time were made using a Duncan 's multiple range test.
Results
Hemodynamics after the initiation of therapy. The
hemodynamic variable s during initiat ion , long-term with-
drawal and reinstitution of therapy with WIN 47203 are
shown in detail for al1 seven patients in Table 1. At initiat ion
of therap y, cardiac index increased from 1.70 ± 0 .39 to
2.30 ± 0 .44 liters/min per m2 (p < 0 .05), while pulmonary
capillary wedge pressure decreased from 24. 1 ± 6.7 to
16.1 ± 7.8 mm Hg (p < 0.05) (Fig. I). It is of interest
that even when an excessive reduction in pulmonary cap-
illary wedge pressure occurred, such as in Patient 6, cardiac
index was neverthele ss, increased substantial1y. Systemic
arterial pressure and heart rate did not change significantly.
The systemic vascular resistance decreased from 1,760 ±
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424 to 1,373 ± 422 dynes's' cm- s (p < 0.05). The im-
provement in cardiac performance observed at initiation of
therapy was maintained during long-term therapy as evi-
denced by similar stroke volume indexes (27.8 ± 5.1 versus
27.9 ± 6.4 ml/rrr' ) and pulmonary capillary wedge pres-
sures( 16. 1 ± 7.8 versus 17.1 ± 7.8 mmH g) when patients
were restudied after an average of 7.4 weeks (Table I).
Effect on symptoms and clinical state. After I to 2
weeks of therapy, all but two patients showed symptomatic
improvement. Their weight remained stable, and the ame-
lioration of symptoms of heart failure was confirmed by an
increase in maximal oxygen uptake from 9.4 ± 1.8 to 10.1
± 2.0 ml/kg per min (p < 0.05) (Fig. 2). Although two
patients (Cases I and 6) manifested steady improvement
during long-term therapy as evidenced by a further increase
in maximal oxygen uptake, the remaining three (Cases 2,
4 and 7) experienced a return of some of their symptoms
CHRONIC THERAPY WITHDRAWAL AND ---il
If--WITH WIN 47203 REINSTITUTION
1
Figure 2. Changes In maximal oxygen uptake during long-term
therapy WIth WIN 47203 in six patients are denoted by numbers.
Maximaloxygenuptake was notmeasuredbeforetherapy in Patient
7.
Figure 1. Changes in cardiac index during short- and long-term
administration of WIN 47203 and during withdrawal and reinsti-
tutionof the drug. Patients aredenotedby numbers. (•••) = cardiac
index not measured before withdrawal in Patient 5.
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which was accompanied by no further increase or even a
slight decrease in maximal oxygen uptake when compared
with that noted earlier. No patient demonstrated any clinical
or laboratorymanifestations of toxicity to WIN 47203. Spe-
cifically, no hematologic or hepatic abnormalities were ob-
served during long-term therapy.
Effects of drug withdrawal. Cardiac index decreased
after withdrawal of WIN 47203 in every patient (Fig. I).
Stroke volume index decreased from 27.9 ± 6.4 to 17.0
± 6.6 rnl/m? (p < 0.05) while pulmonary capillary wedge
pressure increased from 17.1 ± 7.8 to 23.2 ± 12.0 mm
Hg (p < 0.05) and systemic vascular resistance increased
from 1,354 ± 256 to 1,848 ± 399 dynes-s-cm - 5 (p <
0.05). Heart rate and systemic arterial pressure increased
from 82.6 ± 7.2 to 92.3 ± 17.7 beats/min and from 73.8
± 8.1 to 76.6 ± 7.9 mm Hg, respectively, butthesechanges
did not reach significance. The stability of the hemodynamic
deterioration was documented for at least90 minutes in each
patient.
In the two patients (Cases 3 and 5) who had no symp-
tomatic improvement, withdrawal of WIN 47203 produced
hemodynamicand clinical deteriorationthat occurred 26 and
60 hours, respectively, after the last dose of the drug. Sim-
ilarly, hemodynamic and clinical deterioration were also
observed after withdrawal of WIN 47203 in Patients 2. 4
and 7 who, although their condition was improved, expe-
rienceda returnof their symptomsduring long-term therapy.
In contrast, Patients I and 5. who manifested steady im-
provement during long-term therapy, experienced only
hemodynamic deterioration withoutchanges in their clinical
status. The hemodynamic deterioration occurred 36 to 39
hours, respectively, after the last dose of the drug.
Cardiac performance after withdrawal of WIN 47203 was
significantly lower than the control level before therapy;
stroke volume index decreased from 20.3 ± 4.7 to 17.0
± 6.6 ml/rrr' (p < 0.05) and pulmonary capillary wedge
pressure remained unchanged 24.1 ± 6.7 versus 23.2 ±
12.0 mm Hg. This worsening in cardiac performance was
observed most prominently in patients who did not show
clinical improvement or who experienced a return of some
of their symptoms (Cases 2, 4. 5 and 7). It was not noted
in patients who demonstratedsustained improvement during
long-term therapy (Cases 1 and 6). In all patients, reinsti-
tution of therapy with WIN 47203 rapidly reversed the
hemodynamic and clinical deterioration when present (Fig.
I ).
Discussion
Hemodynamic versus clinical response to therapy.
The present study clearly demonstrates that the acute ben-
eficial hemodynamic effects of WIN 47203, an amrinone
analog, are sustained and are drug-dependent during long-
termtherapy in patients with severecongestiveheart failure .
In our patients, the hemodynamic improvement achieved
was not accompanied by any adverse clinical or laboratory
effects. At initiation of therapy with WIN 47203, every
patient exhibited a substantial improvement in cardiac per-
formance as documented by an increase in stroke volume
index and a decrease in pulmonarycapillarywedgepressure.
However, this increased cardiac performance was not ac-
companied by lessening of clinical symptoms in two pa-
tients. Such a disparity between the hemodynamic and clin-
ical benefits of therapy, as well as the poor capacity of the
acute hemodynamic response to predict the extent of sub-
sequent clinical improvement, have been described with
administration of vasodilating agents such as hydralazine
(9) and with inotropic agents such as amrinone (2). Our
present experience with WIN 47203 is consistent with these
previous observations. Indeed, the acute hemodynamic ben-
efits were similar in patients who experienced sustained
symptomatic improvement and in those who did not. More-
over. the patient with the greatest hemodynamic response
(Case 5) had no clinical improvement. These observations
suggest that other factors, such as the severity or rate of
progression of the underlying myocardial disease, or both.
may play a more important role in the clinical response to
a therapeutic intervention than the hemodynamic effect
induced.
Hemodynamic response versus long-term clinical re-
sponse to therapy. Although the acute hemodynamic re-
sponse was not extremely helpful in predicting the clinical
response to WIN 47203 in our patients, the repeat hemo-
dynamic assessment during maintenance , withdrawal and
reinstitution of the drug, with the patient serving as his or
her own control, was extremely useful in understanding the
long-term clinical response to therapy. First, it demonstrated
sustained drug-dependent hemodynamic benefits in all pa-
tients, thereby establishing that the partial recrudescence of
symptoms observed in some cases could not be explained
by tachyphylaxis to the drug. On the contrary. a worsening
of cardiac performance was uniformly observed after with-
drawal of WIN 47203, and was completely reversed by
readministration of the drug. Second, although an improve-
ment of cardiac performanceat rest was maintainedon long-
term therapy, the underlying myocardial disease appeared
to have progressed in some patients. Indeed, after with-
drawal of WIN 47203, at any given left ventricular filling
pressure, stroke volume index was significantly lower than
the value before therapy. Although a rebound phenomenon,
such as that described after withdrawal of acute vasodilator
therapy (10), could have further depressed cardiac perfor-
mance, the stability of the hemodynamic status in our pa-
tients after drug withdrawal militates against this possibility.
Similarly, a rebound phenomenon did not appear to con-
tribute to the deterioration of hemodynamic and clinical
status, which was observed after withdrawal of chronic am-
rinone therapy in patients with severe heart failure (II) .
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Role of progression of myocardial disease in some
patients. Of interest, worsening of the underlying cardiac
performance during long-term therapy was most apparent
in those patients who failed to show clinical improvement
or who experienced some return of symptoms. Indeed . pro-
gression of myocardial disease in these patients may have
further impaired the cardiovascular response to exercise,
and thereby help to explain the worsening of functional
capacity and symptoms.
Although withdrawal of WIN 47203 resulted in both
hemodynamic and clinical deterioration in the majority of
patients. in the two patients whose initial functional im-
provement was fully maintained. only a worsening of hemo-
dynamic status was observed. In these patients. performance
of a graded maximal exercise test both before and after
withdrawal of long-term WIN 47203 therapy might have
enhanced the likelihood of detecting subtle chnical decom-
pensation andshould, therefore. be included insucha protocol.
Whether long-term admin istration of WIN 47203 con-
tributed 10 the progression of the disease, as has been sug-
gested on theoretical grounds with other inotropic agents
(12), is unknown. However, as worsening of cardiac per-
formance was observed after a duration of therapy as short
as 2 weeks, ongoing hemodynamic deterioration may have
beenalreadypresentat the initiationof WIN47203therapy.
Nonetheless, if the underlying disease was indeed progres-
sive, administration of WIN 47203 was apparently unable
to arrest the process despite its sustained effect on cardiac
performance. This problem is difficult to approach because
the underlying cause of the myocardial depression may Itself
be unclear (13) . Most probably. only controlled studies will
be able to adequately address and provide insight into these
issues.
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